Passage Bio Inc(PASG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -11.31 | Insider Own | 7.71% | Shs Outstand | 3.2M | Perf Week | 0.28% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -4.29% | Insider Trans | 25.27% | Shs Float | 3.0M | Perf Month | -21.78% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -2.44 | Inst Own | 43.75% | Short Float | 2.32% | Perf Quarter | -21.25% |
| Income | -0.04B | P/S | - | EPS this Y | 31.85% | Inst Trans | -4.51% | Short Ratio | 3.54 | Perf Half Y | -31.12% |
| Sales | 0.00B | P/B | 2.54 | EPS next 5Y | - | ROA | -69.2% | Short Interest | 0.07M | Perf YTD | -70.17% |
| Book/sh | 1.38 | P/C | 0.47 | EPS past 3/5Y | 34.05% 24.41% | ROE | -169.09% | 52W High | -82.4% ($20.00) | Perf Year | -52.62% |
| Cash/sh | 7.5 | P/FCF | - | Sales past 3/5Y | - | ROIC | -810.41% | 52W Low | 6.99% ($3.29) | Perf 3Y | -72.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 38.14% | Gross Margin | - | Volatility(W/M) | 6.89% 9.02% | Perf 5Y | -97.98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.31 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.22 | EPS Q/Q | 17.7% | Profit Margin | - | RSI (14) | 40.21 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.22 | Sales Q/Q | - | SMA20 | -4.57% ($3.69) | Beta | 1.48 | Target Price | $15.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/07/30 | SMA50 | -18.03% ($4.29) | Rel Volume | 0.86 | Prev Close | $3.33 |
| Employees | 24 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -7.49% - | SMA200 | -44.2% ($6.31) | Avg Volume(3M) | 0.02M | Price | $3.52 |
| IPO | 2020/2/28 | Option/Short | No/Yes | Trades | 195 | Volume | 16,689 | Change | 5.71% |
Passage Bio is a clinical-stage biotech developing AAV-based gene therapies targeting rare central nervous system (CNS) diseases. The company has built its pipeline through a strategic collaboration with the University of Pennsylvania's Gene Therapy Program, with a primary focus on pediatric and adult rare CNS conditions that have very few treatment alternatives, including frontotemporal dementia with progranulin mutations (FTD-GRN), Krabbe disease, and GM1 gangliosidosis.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
PASG has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.9% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 43.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #498 of 594 in the industry
Based on market cap of $11M.
FAQ
What kind of company is PASG?
PASG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PASG?
The market cap of PASG is approximately $11M, ranking 5,402 within its sector.
What is the 52-week high and low for PASG?
PASG has recorded a 52-week high of $20.00 and a low of $3.29.
